Why these two alkaloids deserve their own article

If you read enough kratom coverage you'll see mitragynine and 7-hydroxymitragynine treated as roughly interchangeable — "kratom's active ingredients" lumped together. That framing is not just imprecise; it is actively misleading. The two molecules have very different potencies, very different receptor profiles, and exist in natural leaf in dramatically different amounts. In 2026 the difference between them is also the difference between a legal natural-leaf product and a banned synthetic concentrate.

Mitragynine — the dominant alkaloid

Mitragynine is what makes most of kratom's everyday character. In dried leaf it comprises roughly 1–2% of total mass and 60–70% of the total alkaloid fraction. Pharmacologically it is a partial agonist at the mu-opioid receptor, meaning it binds and activates the receptor but produces only a fraction of the maximum response that a full agonist (like morphine) would.

That partial-agonist behavior is one reason kratom's effect profile differs from classical opioids. Mitragynine also acts at the delta and kappa opioid receptors, at adrenergic alpha-2 receptors, at serotonin receptors, and at others — a polypharmacology that produces the dose-dependent stimulant-to-sedative shift that characterizes natural kratom.

At low doses (effectively low milligrams of mitragynine), the adrenergic and stimulant components dominate: alertness, focus, mood elevation, physical readiness. At higher doses, the opioid-receptor components become more prominent: relaxation, analgesia, sedation. The same plant; the same molecule; very different effect at different doses.

7-hydroxymitragynine — the potent minor alkaloid

7-hydroxymitragynine is structurally similar to mitragynine but with an additional hydroxyl group at the 7-position of the molecule. That small structural change produces a large pharmacological one: 7-OH is a much more potent mu-opioid receptor agonist than mitragynine. Published in vitro studies have placed 7-OH at roughly 10–13× the potency of morphine on a per-molecule basis at that receptor.

In natural leaf, 7-OH is present at less than 0.1% by dry weight and rarely above 2% of total alkaloid content. Despite its high per-molecule potency, the small amount in leaf means its overall contribution to a typical dose is modest, and its activity is buffered by the much larger mitragynine fraction.

Two things to add that are easy to miss:

  • Some 7-OH is generated metabolically from mitragynine in the body. So part of natural kratom's analgesic activity comes from in-vivo 7-OH conversion, not from the small amount present in the leaf itself.
  • Concentrating 7-OH chemically removes its natural-leaf context — the buffering mitragynine, the long tail of other alkaloids, the dose-shape of the plant matrix. The resulting product is a fundamentally different category with much higher dependence and overdose potential than natural leaf, even if the molecule is the same.

The other alkaloids — why "full spectrum" is more than marketing

Mitragynine and 7-OH are the two most studied, but kratom contains over 40 identified alkaloids, several of which are present at meaningful levels:

  • Speciogynine — second most abundant; smooth-muscle relaxant properties
  • Paynantheine — third most abundant; smooth-muscle relaxant, antimalarial activity in vitro
  • Speciociliatine — fourth most abundant; partial opioid receptor activity distinct from mitragynine's
  • Mitraphylline / isomitraphylline — trace amounts, immunomodulatory activity in vitro
  • Rhynchophylline — trace amounts; calcium-channel activity

This is why a careful chemist will tell you that natural kratom is not "the mitragynine plant" — it's a complex botanical preparation whose effects depend on the full alkaloid matrix. "Full spectrum" extracts that preserve the original ratio of all alkaloids are not just a marketing label; they are pharmacologically distinct from purified single-alkaloid products.

What the ratio on a COA actually tells you

Every legitimate kratom product should have a per-batch Certificate of Analysis showing the percentages of mitragynine and 7-OH measured by HPLC at an accredited lab. The ratio between them is the single most diagnostic number on the document:

  • Natural leaf or full-spectrum extract: mitragynine dominates; 7-OH is well under 2% of total alkaloid content. Ratio of mitragynine to 7-OH is typically 30:1 or higher.
  • Synthetically concentrated 7-OH product: 7-OH is comparable to or greater than mitragynine. The ratio inverts. This product is banned in KCPA-compliant states.

That ratio is what KCPA-style legislation regulates. It is also what separates a kratom product that has been on the market for over a decade from a synthetic concentrate that has emerged in the last several years and is the focus of FDA warning letters and consumer alerts.

The bottom line for consumers

You don't need to memorize alkaloid pharmacology to be a smart kratom buyer. You need to know one thing: read the COA, look at the mitragynine and 7-OH percentages, and walk away from any product where 7-OH is anywhere near as high as mitragynine. That single check rules out the most consequential category error in modern kratom commerce.

4 Leaf Herbals publishes selected product- and batch-specific laboratory reports on its Lab Results page. Match the product and lot or batch identifier and review the mitragynine and 7-OH results shown on that report; do not treat it as evidence for a different product or lot.